Skip to main content
TipRanks
Go Ultimate75% OFF

EyePoint Pharmaceuticals (PV3B) AI Stock Analysis

1 Followers
DE:PV3B

EyePoint Pharmaceuticals

(XETRA:PV3B)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
DME Clinical DifferentiationPositive Phase II DME data provide a credible clinical foundation for the company’s remaining lead program. Evidence of comparable vision improvement, stronger anatomical effects, and fewer supplemental injections could support differentiation if replicated in Phase III.
Negative Factors
Wet AMD Clinical FailureFailure of both pivotal wet AMD trials removed the company’s most advanced development path in a major retinal indication and led to program discontinuation. This narrows the pipeline, eliminates a potential near-term route to approval, and increases dependence on DME.

EyePoint Pharmaceuticals (PV3B) vs. iShares MSCI Germany ETF (EWG)

-100%-75%-50%-25%0%25%50%DE:PV3B-97.83%EWG+6.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 30.95M
Dividend Yield
―
Average Volume (3M)
995
Price to Earnings (P/E)
-0.1
Beta (1Y)
1.57
Revenue Growth
-94.40%
EPS Growth
-26.64%
Country
Germany
Employees
214
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

EyePoint Pharmaceuticals Business Overview & Revenue Model

Company Description

EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product p...

EyePoint Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:-23.17%|Next Earnings Date:Mar 04, 2027
Earnings Call SentimentNeutral

The call conveyed significant disappointment following the failure of both Phase III wet AMD trials and the resulting program discontinuation and workforce reduction. However, management expressed confidence in DURAVYU's DME opportunity, supported by the VERONA data, the drug's multi-mechanism rationale, extensive safety experience, ongoing COMO and CAPRI studies, and planned cost reductions. The outlook was mixed, with meaningful clinical and financial execution risks balanced by a focused DME strategy and several stated efficacy and durability advantages.

Positive Updates

DURAVYU Demonstrated Biological Activity in Wet AMD
Although the two Phase III wet AMD trials did not meet the primary endpoint in the full analysis population, DURAVYU consistently demonstrated biological activity, vision improvement, superior reduction in treatment burden, anatomic control measured by OCT, and a favorable safety profile with repeat dosing.

Negative Updates

Phase III Wet AMD Trials Missed the Primary Endpoint
EyePoint announced that its two Phase III wet AMD clinical trials, LUGANO and LUCIA, did not meet the primary endpoint in the full analysis population. Management described the result as deeply disappointing.

Company Guidance

EyePoint expects approximately $118 million in cash, cash equivalents and investments and marketable securities at September 30, 2026, to fund operations into late Q3 2027, excluding any potential cash flows from business development or financing activities that we may undertake or other operational savings and adjustments presently under active review; it announced a workforce reduction of approximately 53%, generating $30 million in annualized savings once fully implemented. COMO and CAPRI enrolled over 550 patients, with top line results expected early in the fourth quarter of 2027 and planned to be reported simultaneously; the primary endpoint is BCVA from baseline to week 52 to 56. The amended supplement-injection criteria allow supplementation for a decline of BCVA greater than five letters from [ VESTO ] study associated on the same visit with an increase in CST of 50 microns or more, compared with the prior threshold of a decline of 10 letters associated with an increase in CST of 50 microns. EyePoint expects to have greater than 300 patients with two years of data at the end of the DME trial, should they be positive, which should we expect, if positive, give us a label for reinjection indefinitely.

EyePoint Pharmaceuticals Risk Analysis

EyePoint Pharmaceuticals disclosed 58 risk factors in its most recent earnings report. EyePoint Pharmaceuticals reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.If we are unable to maintain listing of our securities on Nasdaq or another reputable stock exchange, it may be more difficult for our stockholders to sell their securities.Q3, 2026
2.There is uncertainty regarding our ability to raise additional capital and there is substantial doubt regarding our ability to continue as a going concern.Q3, 2026
3.Our strategic prioritization plan to focus on the Company's late-stage program for DURAVYU in DME and accompanying workforce reduction may not achieve our intended outcome.Q3, 2026

EyePoint Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:PV3B against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MGTXMGTX53Neutral$813.12M9.7985.38%―1365.90%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
RGNXRGNX51Neutral$480.05M-2.26-203.98%―-4.59%8.03%
OCGNOCGN45Neutral$250.82M-3.75643.95%―-11.01%8.03%
EDITEDIT39Underperform$273.18M-2.87-130.43%―7.43%74.00%
OCSOCS38Underperform$456.20M-4.51-39.51%――31.72%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:PV3BOCGNRGNXEDITMGTXOCSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:PV3B and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:PV3BEyepoint Pharma0.25-11.29-97.82%
OCGNOcugen Inc0.74-0.42-36.29%
RGNXRegenXBio Inc.7.26-4.54-38.47%
EDITEditas Medicine Inc.1.77-0.65-26.86%
MGTXMeiragtx Holdings8.320.8611.53%
OCSOculis Holding Ag7.39-11.87-61.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.